Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal implant for intravitreal use. It treats diabetic macular edema in adults by delivering sustained anti‑inflammatory therapy directly to the retina, reducing fluid accumulation and improving visual function.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmology clinics and specialty pharmacies worldwide, ensuring consistent quality, regulatory compliance and reliable cold‑chain logistics where required, with dedicated technical support and documentation for regulatory submissions.

Iluvien, an ophthalmic corticosteroid, is indicated for retinal conditions characterized by vascular leakage and inflammation, specifically diabetic macular edema that persists despite prior therapy.

Diabetic macular edema (chronic): reduces retinal fluid accumulation, stabilizes or improves visual acuity, and provides sustained therapy for up to 36 months. Diabetic macular edema (refractory to anti‑VEGF therapy): delivers continuous corticosteroid exposure, offering an alternative mechanism of action to control edema.

Fluocinolone acetonide released from the Iluvien implant may be associated with ocular adverse reactions.

Common Side Effects: - Increased intraocular pressure (IOP) - Cataract formation or progression - Blurred or decreased vision - Ocular discomfort or pain - Floaters or visual disturbances - Mild anterior chamber inflammation

Serious or Rare Side Effects: - Endophthalmitis (intraocular infection) - Retinal detachment or tear - Severe IOP elevation requiring surgical intervention - Persistent macular edema despite therapy - Implant migration or dislocation

When prescribing Iluvien, clinicians should consider patient‑specific risk factors and monitor ocular status regularly. - Monitor intraocular pressure: schedule periodic IOP measurements to detect elevation early. - Assess cataract development: evaluate lens status at each follow‑up visit. - Screen for ocular infection: avoid implantation in eyes with active infection. - Evaluate glaucoma history: contraindicated in uncontrolled glaucoma. - Pregnancy and lactation: safety unknown; use only if potential benefit justifies risk. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Iluvien may interact with other ocular or systemic agents; awareness of potential additive effects is essential.

Major Interactions (Avoid): - Concurrent intraocular corticosteroids: additive risk of intraocular pressure rise. - Systemic immunosuppressants (e.g., systemic steroids, biologics): may increase infection risk. - CYP3A4 inhibitors (e.g., ketoconazole) in patients with systemic exposure: theoretical increase in systemic levels.

Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate ocular irritation. - Antihypertensive eye drops (e.g., beta‑blockers): monitor IOP response. - Anticoagulants: consider bleeding risk during implantation procedure.